KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS.

Glenn J Jaffe, Gábor Deák, Kara Gibson, Rahul N Khurana, Eric Nudleman, Yuichiro Ogura, Ursula Schmidt-Erfurth, Tracey Wang, Peter D Westenskow, David Wong, Glenn Yiu, Jeffrey R Willis

Retina 45(11) 2003-2011

PMID40668667
PMCIDPMC12548813
DOI10.1097/IAE.0000000000004572
发表日期2025-07-16
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1.:CONSORT/入组流程图;Fig. 2.:AI 判定为 other;Fig. 3.:AI 判定为 other;Fig. 4.:AI 判定为 other;captionless-figure:AI 判定为 other;另有 1 张未列出。
摘要

摘要

BACKGROUND/PURPOSE: To assess the effects of faricimab versus aflibercept on epiretinal membrane (ERM) formation in eyes with diabetic macular edema. METHODS: Post hoc analysis of phase 3 YOSEMITE/RHINE trial data in eyes with diabetic macular edema receiving faricimab every 8 weeks (Q8W), faricimab treat-and-extend (T&E; up to Q16W depending on central subfield thickness and best-corrected visual acuity), or aflibercept Q8W for 100 weeks. RESULTS: ERMs developed in 3.8% (23/602) of eyes treated with faricimab Q8W, 5.1% (31/608) with faricimab T&E, and 7.6% (45/590) with aflibercept Q8W at 100 weeks. ERMs were less likely with faricimab Q8W versus aflibercept Q8W (odds ratio [OR] 0.48, 95% confidence interval [CI] 0.29-0.81, P = 0.0055). The mean (SD) best-corrected visual acuity at 100 weeks in eyes with and without ERMs were 69.2 (13.6) letters [20/40 Snellen] versus 73.8 (13.1) [20/40 Snellen], respectively; the mean (SD) CSTs were 315.8 (99.2) versus 274.6 (74.1) µ m. Faricimab T&E dosing intervals were extended ≥ Q12W in 79.7% of eyes without ERMs versus 50.0% with ERMs. CONCLUSION: Risk of ERMs was 52% lower with faricimab Q8W versus aflibercept Q8W over 100 weeks in eyes with diabetic macular edema, suggesting a potential role for faricimab in reducing pre-retinal fibrotic proliferation. The results may help inform physician/patient decision-making when initiating intravitreal therapy. TRIAL REGISTRATION: NCT03622580 and NCT03622593.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Patient flow diagram for the post hoc analysis of ERM formation in the phase 3 YOSEMITE and RHINE trials.
非 KM Figure
Fig. 2.Fig. 2. Cumulative proportion of eyes without ERMs at baseline that developed ERMs after 1 and 2 years (weeks 52 and 100) (ERM analysis population).
非 KM Figure
Fig. 3.Fig. 3. A. BCVA. B. CST. C. Proportion of eyes with IRF and SRF, and D , macular leakage at baseline and year 2 (week 96 or 100) in eyes with and without ERM formation (ERM analysis population).
非 KM Figure
Fig. 4.Fig. 4. Proportion of eyes in the faricimab T&E arm on each treatment interval at year 2 (week 96) among eyes with and without ERM formation during the study (ERM analysis population).
非 KM Figure
captionless-figurecaptionless-figure
非 KM Figure
captionless-figurecaptionless-figure
非 KM Figure